Please login to the form below

lung cancer

This page shows the latest lung cancer news and features for those working in and with pharma, biotech and healthcare.

New dosing option for AZ’s Imfinzi approved in the EU and UK

new dosing option in locally advanced, unresectable non-small cell lung cancer (NSCLC). ... The new dosing regimen is consistent with Imfinzi’s approved dosing in extensive-stage small cell lung cancer (ES-SCLC).

Latest news

Roche’s tiragolumab plus Tecentriq combo wins FDA breakthrough therapy designation

The BTD covers the combination treatment in the first-line setting for people with metastatic non-small cell lung cancer (NSCLC), whose tumours have high PD-L1 expression and no EGFR ... outcomes for people with certain types of lung cancer,” said Levi
Amgen aims for first KRAS inhibitor approval in the US

metastatic non-small cell lung cancer (NSCLC), who have received at least one prior systemic therapy. ... Amgen is due to submit the detailed results from the phase 2 study to the International Association for the Study of Lung Cancer World Conference on
Jazz Pharma’s SCLC drug fails to meet primary endpoint in combo trial

Drug combination failed to improve overall survival rate. Jazz Pharmaceuticals and PharmaMar have revealed that their small cell lung cancer (SCLC) therapy lurbinectedin has failed to meet the primary endpoint in
Merck strengthens oncology pipeline with $2.75bn VelosBio deal

Merck &Co (MSD) has agreed to acquire VelosBio for $2.75bn, giving MSD access to a number of potential cancer treatments in the process. ... breast cancer (TNBC), hormone receptor-positive and/or HER2-positive breast cancer and non-squamous non-small
Keytruda growth helps Merck to offset COVID-19 impact in Q3

In the third quarter, sales of Keytruda grew by 24% to $2.2bn reflecting growing momentum in a number of non-small cell lung cancer indications, as well as uptake in ... other areas including adjuvant melanoma and bladder cancer.

More from news
Approximately 108 fully matching, plus 834 partially matching documents found.

Latest Intelligence

Successful product commercialisation: what can we learn from the rare disease setting?

With an increasing number of drug trials in crowded markets such as oncology (for example, in non-small cell lung cancer and multiple myeloma), understanding patient needs is not only critical
Growing evidence supports the important role of biosimilars in healthcare

The fatality rate was higher for patients with lung cancer and non-Hodgkin Lymphoma, at 15.7% and 9.4%, respectively. ... It also builds on previous studies demonstrating the cost-effectiveness of Zarxio as primary prophylaxis within patients with lung
Unlocking the potential of precision medicine in oncology

Targeted therapies. Furthermore, by following a similar trajectory in the treatment of non-small cell lung cancer (NSCLC), where we are studying specific alterations in the epidermal growth factor receptor (EGFR), ... We are following a similar approach
BiTE* platform and the evolution toward off-the-shelf immuno-oncology approaches

the other is designed to engage with any tumour-specific antigen, for example DLL3 in small-cell lung cancer, PSMA in prostate cancer and CLDN18.2 and MUC17 in gastric or ... T cells only become activated and proliferate, with the goal of staying
Addressing the payer-regulator evidence gap in early-stage cancer

As part of the Lung Ambition Alliance, a partnership with the International Association for the Study of Lung Cancer (IASLC), Guardant Health and the Global Lung Cancer Coalition (GLCC), AstraZeneca is ... working to validate relevant endpoints to

More from intelligence
Approximately 1 fully matching, plus 61 partially matching documents found.

Latest appointments

Merck’s R&D chief Roger Perlmutter heads for the exit as Dean Li takes the helm

newly-diagnosed non-small cell lung cancer (NSCLC) patients.
Astellas bolsters oncology clinical development leadership

breast cancer, leukaemia, lung cancer and prostate cancer. ... of Medicine and the University of Texas MD Anderson Cancer Center.
Iris Pauporté joins OSE Immunotherapeutics

Pauporté will lead the clinical development of the firm's lung cancer candidate Tedopi, which is currently in phase III trials, and will be responsible for exploring the drug's potential ... She brings over 20 years of biomedical and clinical research
Astellas promotes John Demaree

Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib). ... Mark Reisenauer, senior vice
Merck appoints ex-Pfizer exec as global head of oncology

lung cancer therapy, which is expected in 2017. ... bring new therapeutic options to patients living with cancer.

More from appointments
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest from PMHub

Delphi Technique Virtual Co-creation: A Customer Story

The client’s main objectives were to:. Determine the current barriers to biomarker testing and biomarker-based treatment for non-small cell lung cancer (NSCLC), including differences in regional access and
September 2020: diversity and inclusion in clinical trials round-up

The Hispanic population is underrepresented in lung cancer trials despite experiencing different health outcomes to white people. ... The Hispanic population is generally not represented in lung cancer trials because of limited access and few research
July 2020: diversity and inclusion in clinical trials round-up

Black people are among those who typically suffer poorer health outcomes from lung cancer. ... Early next year, a Stand Up To Cancer Innovation Summit will launch the project, which will bring together lung cancer experts with researchers specializing in
Are you using Patient-Reported Outcomes (PROs) in your oncology trials? If not, why not?

Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. ... 2017 Jul 11; 318(2):197-198. Denis F, Basch E et al. Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine
Early diagnosis underpins NHS cancer strategy

lung cancer, have shown the value of bringing these kinds of services closer to patients’ homes. ... For example, most lung cancer diagnoses are made at stage four.

More from PMHub
Approximately 2 fully matching, plus 15 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Account Director – Creative Healthcare Communications: Competative

Healthcare Senior Account Manager: Competitive

Healthcare Account Director: Competitive

Healthcare Lead Copywriter: Competitive

Medical Editor: Competitive

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

Account Manager Healthcare / Pharmaceutical Sector: Negotiable Salary

PMHub

Add my company

11 London

11 London is a strategic and creative agency working in the fields of health and humanity – complex areas, but...

Latest intelligence

The search for effective drug treatments for COVID-19: PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...
AstraZeneca’s focus on diagnosing and managing chronic kidney disease: People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story: How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....